Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.027 HKD | 0.00% | -3.57% | -20.59% |
2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Sales 2022 | 73.92M 9.44M | Sales 2023 | 72.58M 9.27M | Capitalization | 160M 20.45M |
---|---|---|---|---|---|
Net income 2022 | 131M 16.73M | Net income 2023 | 129M 16.48M | EV / Sales 2022 | 2.42 x |
Net cash position 2022 | 29.22M 3.73M | Net cash position 2023 | 1.68M 215K | EV / Sales 2023 | 2.18 x |
P/E ratio 2022 |
1.99
x | P/E ratio 2023 |
1.52
x | Employees | 169 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.85% |
1 week | -3.57% | ||
Current month | -10.00% | ||
1 month | -20.59% | ||
3 months | -3.57% | ||
6 months | -34.15% | ||
Current year | -20.59% |
Managers | Title | Age | Since |
---|---|---|---|
Yi Xie
CEO | Chief Executive Officer | 61 | - |
Hong Wu
DFI | Director of Finance/CFO | 52 | - |
Yong Cheng
BRD | Director/Board Member | 61 | 13-12-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yi Lou
BRD | Director/Board Member | 66 | 08-10-05 |
Sau Kuen Wong
BRD | Director/Board Member | 61 | 08-04-30 |
Yi Xie
CEO | Chief Executive Officer | 61 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.027 | 0.00% | 440 000 |
24-04-25 | 0.027 | -10.00% | 830,000 |
24-04-24 | 0.03 | +15.38% | 310,000 |
24-04-23 | 0.026 | -3.70% | 200,000 |
24-04-22 | 0.027 | -3.57% | 1,010,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 02:24 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.59% | 8.24M | |
+24.17% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.45% | 233B | |
+6.04% | 201B | |
-10.51% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- 858 Stock